SCHEMBL21884475

SCHEMBL21884475

CS(=O)(=O)c1ccc(O)c(C(=O)NC(=N)N)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
KDM1A O60341 2/20 0.41
F10 P00742 4/20 0.40
PLAU P00749 4/20 0.40
PLAT P00750 4/20 0.40
F2 P00734 3/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
G6PD P11413 1/20 0.37
IDE P14735 1/20 0.37
ALOX5 P09917 1/20 0.37
ENPP2 Q13822 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 1/20 0.36
IKBKB O14920 1/20 0.36
CHUK O15111 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125185 0.85 TDP1 (0.42) LMNAALDH1A1G6PDIDEMEN1
Hydrochloric Acid SCHEMBL8804424 0.84 TDP1 (0.41) LMNAALDH1A1G6PDIDEMEN1
Hydrochloric Acid SCHEMBL8803119 0.83 LMNA (0.57) LMNAALDH1A1MEN1KMT2APOLB
SCHEMBL7783640 0.76 IKBKB (0.35) LMNAKDM1AMEN1KMT2AIKBKB
Hydrochloric Acid SCHEMBL8804082 0.76 SLC6A9 (0.54) LMNAKDM4EALDH1A1HPGDPOLB
SCHEMBL8445926 0.76 PLAU (0.48) F10PLAUPLATF2ALOX5
SCHEMBL23875335 0.75 P2RX1 (0.57) MEN1KMT2AIKBKBCHUK
SCHEMBL21884644 0.75 PPIA (0.50) LMNAF10PLAUPLATF2
SCHEMBL21884653 0.75 PLAU (0.61) F10PLAUPLATF2KDM4E
SCHEMBL21884580 0.75 PLAU (0.53) F10PLAUPLATF2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 US disclosed
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 US disclosed
WO-2020061473-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 LMNA 1819/4885KDM1A 3228/4885F10 4684/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 LMNA 2213/4885KDM1A 4569/4885F10 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.